SCHEMBL9905290

SCHEMBL9905290

c1ccc(-c2nncs2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.59
RAB9A P51151 7/20 0.59
NPC1 O15118 6/20 0.59
MAPT P10636 3/20 0.59
ATM Q13315 1/20 0.59
LMNA P02545 3/20 0.50
CCR1 P32246 2/20 0.50
CCR5 P51681 2/20 0.50
CCR8 P51685 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
METAP1 P53582 1/20 0.50
BLM P54132 1/20 0.50
HIF1A Q16665 1/20 0.50
DOHH Q9BU89 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
PDE10A Q9Y233 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.48
ALDH1A1 P00352 6/20 0.48
TP53 P04637 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29945025 1.00 KDM4E (0.59) KDM4ERAB9ANPC1MAPTATM
Propanol SCHEMBL27923176 0.87 KDM4E (0.46) KDM4ERAB9ANPC1MAPTATM
SCHEMBL30921015 0.78 GOT1 (0.33) KDM4ERAB9ANPC1MAPTATM
SCHEMBL1178875 0.74 HSP90AA1 (0.34) KDM4ERAB9ANPC1MAPTATM
SCHEMBL6897351 0.74 CYP19A1 (0.37) KDM4ERAB9ANPC1MAPTATM
SCHEMBL1424929 0.74 KDM4E (1.00) KDM4ERAB9ANPC1MAPTATM
SCHEMBL22250429 0.74 IDO1 (0.39) KDM4ERAB9ANPC1MAPTATM
SCHEMBL572719 0.70 PDPK1 (0.45) KDM4ERAB9ANPC1MAPTCYP1A2
Dipyridyl SCHEMBL29351528 0.69 KDM4E (1.00) KDM4ERAB9ANPC1MAPTATM
Dipyridyl SCHEMBL29907716 0.69 KDM4E (1.00) KDM4ERAB9ANPC1MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023277-A1 CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME VISEN MEDICAL, INC. 2022-01-27 US claimed
US-12110283-B2 Carbonic anhydrase targeting agents and methods of using same VISEN MEDICAL, INC. (US) 2024-10-08 US disclosed
US-20220023277-A1 CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME VISEN MEDICAL, INC. 2022-01-27 US disclosed
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-11-23 US disclosed
EP-3216798-A2 KETOLIDE COMPOUNDS Wockhardt Limited (IN) 2017-09-13 EP disclosed
US-9745339-B2 Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-08-29 US disclosed
EP-2673285-B1 KETOLIDE COMPOUNDS WOCKHARDT LTD (IN) 2017-07-19 EP disclosed
CN-105669803-A KETOLIDE COMPOUNDS 沃克哈特有限公司 2016-06-15 CN disclosed
US-20160083412-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2016-03-24 US disclosed
CN-103384676-B Ketolactone compounds WOCKHARDT LTD. (IN) 2016-02-03 CN disclosed
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2016-01-14 US disclosed
US-9175031-B2 Ketolide compounds WOCKHARDT LIMITED (IN) 2015-11-03 US disclosed
CN-104395335-A Ligands for antibody and fc-fusion protein purification by affinity chromotography iv GRAFFINITY PHARMACEUTICALS GMBH 2015-03-04 CN disclosed
EP-2812346-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV Graffinity Pharmaceuticals GmbH (DE) 2014-12-17 EP disclosed
WO-2014020152-A1 LIGANDS FOR APHERESIS AND IMMUNOABSORPTION GRAFFINITY PHARMACEUTICALS GMBH (DE) 2014-02-06 WO disclosed
US-20140005133-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2014-01-02 US disclosed
EP-2673285-A1 KETOLIDE COMPOUNDS Wockhardt Limited (IN) 2013-12-18 EP disclosed
WO-2013117707-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-08-15 WO disclosed
WO-2012076989-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B KDM4E 3660/4885RAB9A 3122/4885NPC1 3852/4885
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B KDM4E 3539/4885RAB9A 3135/4885NPC1 3817/4885
US-12110283-B2 Carbonic anhydrase targeting agents and methods of using same CA4, CA12, CA9 KDM4E 2005/4885RAB9A 2829/4885NPC1 1593/4885
US-20160083412-A1 KETOLIDE COMPOUNDS AKR1C3, AKR1D1, AKR1C1 KDM4E 313/4885RAB9A 891/4885NPC1 452/4885
US-20140005133-A1 KETOLIDE COMPOUNDS AKR1C3, AKR1D1, AKR1C1 KDM4E 298/4885RAB9A 1143/4885NPC1 458/4885
US-20220023277-A1 CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME CA4, CA12, CA9 KDM4E 2005/4885RAB9A 2829/4885NPC1 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.